Industry landscapes
Industry report

Funding and advertised pay are reported in USD; filed accounts retain their stated source currency and basis.

Exchange-rate basis

Indicative conversions use ECB reference rates dated 2026-09-14, applied consistently across all periods. They are not historical exchange rates. Indian rupees may use crore (1 crore = 10 million); other currencies use K, M and B. CSV downloads, source documents and quoted news headlines retain their original currencies.

THE THE UNITED STATES EDITION 2026

the United States’s
life sciences industry,
in focus.

The companies, capital and talent shaping life sciences in the United States. Find the leaders. Understand the segments. See where the activity is.

Snapshot: Funding in USD
Illustrated cover for Life Sciences Industry Landscape of the United States
US
COMPANIES · CAPITAL · TALENT

An industry ecosystem,
measured in context.

Life Sciences illustration
MEET THE COMPANIES

Explore the United States’s life sciences leaders

24 featured companies from the funding, hiring, revenue and team-size leaderboards.

Expand panel +
Life Sciences company highlights in the United States, snapshot 5 August 2026
Company
BeiGenebeigene.com$5.07B—1,090$5.34BFYFY2025 filing
Modernamodernatx.com$4.15B—1,312—
Celgenecelgene.com$3.08B—4,891—
Verilyverily.com$2.81B—1,564—
Novavaxnovavax.com$2.73B—184—
Invitaeinvitae.com$2.5B—1,700—
GRAILgrail.com$2.33B—491—
Amyris$2.23B———
Brooks Automationbrooks.com—13 roles1,836—
Insuletinsulet.com—13 roles2,600—
AssistRxassistrx.com—12 roles1,000—
Haemoneticshaemonetics.com—12 roles3,034—
HearUSAhearusa.com—12 roles497—
Intuitive Surgicalintuitivesurgical.com—12 roles9,425—
ResMedresmed.com—12 roles10,140$5.15BFYFY2025 filing
Veeva Systemsveeva.com—12 roles6,744Financial figure available in RadarView in Radar
23andMe23andme.com——755—
Agilentagilent.com——5,968Financial figure available in RadarView in Radar
Alnylamalnylam.com——2,100Financial figure available in RadarView in Radar
Aptar Pharmaaptar.com——13,500Financial figure available in RadarView in Radar
Bio Radbio-rad.com——11,479Financial figure available in RadarView in Radar
BioMarin Pharmaceuticalbiomarin.com——2,124$3.22BFYFY2025 filing
Biogenbiogen.com——9,482$9.89BFYFY2025 filing
Dentsply Sironadentsplysirona.com——15,000$3.68BFYFY2025 filing
24 featured companies

Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗

Startup discovery

Recorded classifications only
THE KEY SIGNALS

Life Sciences industry KPIs in the United States

A few useful ratios bring the size of this ecosystem into perspective.

5 August 2026
Hiring participation6.7%

1,579 of 23,666 tracked companies have open roles.

Funding participation40.3%

9,529 of 23,666 tracked companies have a recorded round.

Top 3 funding share2.4%

Share of disclosed capital received by the three largest recorded recipients.

Median disclosed round$2.35M

Midpoint of 20,912 rounds with a disclosed amount.

Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 2.4% of disclosed capital, while 59.7% of tracked companies have no recorded funding round.

Explore the segments →
CAPITAL & COMPANY FORMATION

How the United States life sciences has grown

Recorded company formation and disclosed funding across the complete annual series shown.

Expand panel +
2016 — 2025

Disclosed funding by year

Sum of recorded funding rounds · USD

the United States life sciences
$0$15.77B$31.55B$47.32B$63.1B2016: $21.03B20162017: $29.5B20172018: $37.7B20182019: $35.66B20192020: $52.89B20202021: $55.35B20212022: $38.99B20222023: $27.33B20232024: $33.72B20242025: $33.07B2025
View the numbers
Annual life sciences funding and company formation in the United States
YearFunding (USD)FoundedRaising
2016$21.03B11841622
2017$29.5B11591670
2018$37.7B11571745
2019$35.66B11521747
2020$52.89B11561868
2021$55.35B8391743
2022$38.99B6001497
2023$27.33B5031515
2024$33.72B3271382
2025$33.07B1271494
WHERE CAPITAL SITS

Funding concentration

Share of all disclosed company funding.

  • BeiGene1.0%
  • Moderna0.8%
  • Celgene0.6%
  • Other companies97.6%

Funding by stage

22,828 recorded rounds since 2016

NUMBER OF ROUNDS
Seed & Angel4165 18.2%
Series A–B6212 27.2%
Series C+ / PE2059 9.0%
Grants, debt & other10392 45.5%

Recent recorded rounds

Latest recorded rounds · USD
8 rounds

Swipe or scroll horizontally to browse.

Series D05/2026
MiRus $1.5B

Backed by Boston Scientific.

Post IPO05/2026
Quince Therapeutics $187M

Backed by Balyasny Asset Management and Affinity Asset Advisors and others.

Series B05/2026
CREATE Medicines $122M

Backed by Newpath Partners and Hatteras Venture Partners and others.

Series A05/2026
Latus $97M

Backed by 8VC and DCVC and others.

Largest and notable recorded rounds

Each card is one recorded round
10 cards

Swipe or scroll horizontally to browse.

Series B02/2017
GRAILgrail.com$1.21B

Backed by Arch Venture Partners and Johnson & Johnson Innovation and others.

Series D04/2024
Xairaxaira.com$1B

Backed by Arch Venture Partners and Foresite Labs and others.

Series B10/2025
Kailerakailera.com$600M

Backed by Bain Capital Private Equity and Adage Capital Management and others.

THE BUSINESS BEHIND THE ACTIVITY

Revenue, profitability & financial strength

Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.

Expand panel +
USD · millions · consolidated

Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.

FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 377 reporting entities from 961 eligible matches.

Revenue in covered accounts$239,975.9m

Sum of reporting-entity revenue; not the United States market sales.

Net profit / loss$-941.7m

Combined result for the same cohort.

Aggregate net margin-0.4%

Combined net income ÷ combined revenue.

Median company revenue$38.7m

The middle covered reporting entity.

Profitable entities+21.2%

80 of 377 covered entities.

Top-five concentration+51.0%

Share of covered revenue from the five largest entities.

Annual account trend

Reported cohort totals by year; coverage is stated for every period.

Bar height shows revenue. Changes in coverage can affect totals.

Profitability has two perspectives

FY2025 · 377 reporting entities

Open the company accounts

Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.

377 reporting entities
Continue your financial research in Radar

Explore full company accounts and filings.

View financials in Radar ↗
THE UNITED STATES · INDUSTRY COHORTS

How does life sciences compare?

Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.

IndustryCovered / eligibleRevenue totalMedian revenueNet profit / lossAggregate marginProfitable shareOverlap

Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.

Coverage, calculations & financial sources

Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.

The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.

Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.

DIGITAL FOOTPRINT

Web traffic, app reach and release cadence

How the the United States companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.

Busiest websites

132 of the 23,668 companies on this page carry a measured traffic record (0.6%); these are the largest of those, by monthly visits. The median among them is 189,807 visits.

CompanyMonthly visitsAuthorityMobile
Ancestryancestry.com31,934,9287970.3%
Academiaacademia.edu27,026,9167141.9%
Consensusconsensus.app4,313,9125817.1%
Dexcomdexcom.com3,223,8355981.8%
Hungryroothungryroot.com2,941,1065088.6%
Noomnoom.com1,939,0115486.8%
Vitacost.comvitacost.com1,716,5754832.9%
Seedseed.com1,401,3725179.4%
Exact Sciencesexactsciences.com1,380,3834787.3%
Agilentagilent.com1,295,3275143.1%

Visits and authority are third-party web estimates, not company-reported figures.

Most-installed apps

537 of these companies (2.3%) publish at least one Android app — 1,025 apps in all, carrying 116.7M installs between them.

AppInstallsRatingStore category
Instant Heart Rate: HR MonitorInstant Heart Rate31.3M3.7Health & Fitness
Noom: Weight Loss & GLP-1 CareNoom22.8M4.1Health & Fitness
Ancestry: Family History & DNAAncestry13.1M4.6Books & Reference
Academia.eduAcademia4.8M4.7Education
myAir™ by ResmedResMed4.3M4.2Medical
Zero - Intermittent FastingZero4M3.8Health & Fitness
23andMe - DNA Testing23andMe3.1M4.7Health & Fitness
KardiaAliveCor2.2M4.7Medical
Dexcom G7Dexcom1.9M3.2Health & Fitness
Dexcom ClarityDexcom1.7M3.9Health & Fitness

Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.

App reach by segment

The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).

SegmentAppsInstallsLeading appRelease trend
Disease Self Management22152.3MInstant Heart Rate: HR Monitor 31.3M
Wearable Technology21449.5MKardia 2.2M
Healthcare It17137MLivongo 789.2K
Cardiac And Vascular Disorders8035MMyZio 648.1K
Nutraceuticals Tech8927.8MNoom: Weight Loss & GLP-1 Care 22.8M
Fitness & Wellness Tech5827.7MZero - Intermittent Fasting 4M
Employee Health It722.9MNewtopia 19.4K
Genomics4020.7MAncestry: Family History & DNA 13.1M

A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.

Release cadence by quarter

New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.

2023Q2: 302023Q2: 112023Q22023Q3: 212023Q3: 202023Q32023Q4: 222023Q4: 232023Q42024Q1: 232024Q1: 292024Q12024Q2: 292024Q2: 112024Q22024Q3: 392024Q3: 512024Q32024Q4: 332024Q4: 542024Q42025Q1: 342025Q1: 412025Q12025Q2: 262025Q2: 412025Q22025Q3: 292025Q3: 962025Q32025Q4: 232025Q4: 1002025Q42026Q1: 292026Q1: 1322026Q1

Darker bars are new releases, lighter bars apps updated. 933 of 1,025 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.

INSIDE THE INDUSTRY

The the United States life sciences market map

Explore the segments behind the headline numbers.

Expand panel +

Where companies are building

Rank segments by scale, hiring or disclosed funding.

Enterprise tech14,552
Medical devices5,358
Biopharmaceuticals4,752
Healthtech3,751
Enterprise software3,269
Deep tech3,205
Consumer digital3,138
In vitro diagnostics1,146
Saas1,145
Nutritional formula992
Healthtech saas935
Iot in healthcare679

Companies can sit in several segments. Counts and funding overlap.

SEGMENT TO EXPLORE

Enterprise tech

The largest measured segment in this report snapshot.

14552companies
8.6%have hiring activity

1251 companies hiring · $449.96B disclosed funding

Explore in Radar

How companies make money

Common revenue models; a company can use more than one.

Physical commerce11,293
E-commerce - product9,534
Subscription6,484
Fee-for-service4,106
Commission on transaction606
Advertising464
E-commerce - service259
Sponsorship37
THE COMPANIES IN MOTION

Who is listing, hiring leaders, launching and winning work

Recorded corporate activity linked to companies in this landscape.

Expand panel +
Recent corporate headlines 10 dated reports
Mergers & acquisitionsesperion.com ↗

Esperion Therapeutics (Nasdaq: ESPR) (Esperion), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED, a leading investment firm focused exclusively on healthcare industries, have announced that they have entered into a definitive agreement under which funds managed by ARCHIMED will acquire Esperion in a transaction valued at up to approximately US$1.1 billion in total equity value (including a non-tradeable contingent value right (CVR) tied to the achievement of certain commercial-based milestones).

Mergers & acquisitionscandidco.com ↗

Candid is choosing the M&A route instead, opting to accept a $2 billion buyout offer that gives UCB the biotech’s pipeline of T cell engagers for immune disorders.

Mergers & acquisitionscandidrx.com ↗

UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for China-made autoimmune assets in 2026.

Mergers & acquisitionsbiomarin.com ↗

President and CEO Alexander Hardy said the Amicus deal closed last week and described it as “a new and exciting chapter” that increases portfolio diversification.

Funding roundssenseonics.com ↗

With these funds, combined with net proceeds from a recent $80 million public offering, the company reports cash and cash equivalents balance of approximately $64.6 million as of March 31, 2026.

Funding roundscnspharma.com ↗

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) has announced a private placement expected to generate approximately $22.5 million in gross proceeds, according to a press release.

Funding roundscabalettabio.com ↗

Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA ), a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten offering of 51,725,000 shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $150 million.

Funding roundstechcyte.com ↗

Techcyte has now raised a total of $50.4M in total equity funding and is backed by Mayo Clinic, Van Tuyl Companies, and Zoetis.

Mergers & acquisitionsvikingtherapeutics.com ↗

Prudential Financial Inc. bought a new stake in Viking Therapeutics in the 2nd quarter valued at about $196,000.

IPO activityevommune.com ↗

Evommune had issued 9,375,000 shares in its IPO on November 6th. The total size of the offering was $150,000,000 based on an initial share price of $16.00.

Full recorded event mix

Top 10 categories among 23,605 recorded events in the 24-month window.

Earnings
6,741
Funding rounds
3,830
Leadership moves
3,725
Mergers & acquisitions
2,260
IPO activity
1,708
Company announcements
1,562
Contracts
784
Lawsuit
755
Asset acquisitions
584
Regulatory
520
7 activity cards

Swipe or scroll horizontally to browse.

IPO pipeline

91 companies with recorded IPO activity

Evommune ↗

IPO · NYSE15 reports

IPO · Nasdaq1 reports

IPO · Nasdaq Global Select Market5 reports

senseonics ↗

Follow-on Offering · NYSE1 reports

IPO · Nasdaq2 reports

Follow-on Offering · NASDAQ1 reports

Altimmune ↗

Follow-on Offering · NASDAQ1 reports

Nektar ↗

Follow-on Offering · NASDAQ2 reports

Leadership moves

248 tracked people moves

Claire Mazumdar

Appointment Chief Executive Officer

Natalie Holles

Appointment Chief Executive Officer

Elisabet de los Pinos

Resignation Previously Chief Executive Officer

Rejoni ↗
John Nealon

Appointment Chief Executive Officer

Scott Ullem

Resignation Previously Chief Financial Officer

Theodora (“Doretta”) Mistras

Appointment Chief Financial Officer

Agilent ↗
Michael Buckner

Appointment Chief Legal Officer

Craig Eagle

Resignation Previously Chief Medical Officer

Product launches

Products, platforms and features in the recorded window

Checkerspot ↗
Algolein

microalgae-derived oil

Ceres ↗
Endura stack

Solid Oxide Fuel Cell Stack

withZeta.ai

AI platform for rare cancer drug discovery

Nutty Puffs

Snack

Nutty Trail Mix

Snack

Cyanotech ↗
high-purity spirulina extracts

Dietary Supplements

NU Skin ↗
Prysm iO

Handheld wellness device

AI ultrasound pregnancy tool

AI ultrasound pregnancy tool

Litigation

32 tracked suits

Company
tesaro v anaptysbio

Anticipatory breach and declaratory judgment dispute over license agreementCivil · Ongoing

Company
tesaro v Anaptys

Contract breachCivil · Dismissed

Earnings pulse

Reported company results in the recorded window.

903companies
7,390period observations
16.0%median reported growth

Median across 3,019 reported growth observations; companies may contribute multiple periods.

Mergers and acquisitions

Company-linked deal reports; status is preserved as recorded.

Acquirer → targetStatusDateValue / context
novartis→Alcon ↗Announced2026-06-25Not stated in snapshot
merck sharp & dohme→Artiva ↗Terminated2026-06-25$1.9B
regeneron pharmaceuticals→23andMe ↗Announced2026-05-19$256.0M
UCB S.A.→Candid ↗Announced2026-05-05$2.0B
archimed→Esperion Therapeutics ↗Announced2026-05-05$1.1B
integrated wealth→Viking Therapeutics ↗Completed2026-05-04$230.0K

A discussion or rumour is not a completed transaction. An unstated value is not zero.

PEOPLE & OPPORTUNITY

The talent market

45,131 postings in the preceding 12 months. The full 62,665-posting snapshot covers 1,627 employers.

Expand panel +

Most advertised job titles

Assistant Manager1,487
General Manager622
Auto Detailer287
Cook254
Health And Wellbeing Coach231
Patient Service Representative225
1 internship postings

3,886 tracked postings mention remote work.

The seniority mix

26,885 postings specify a level.

unspecified
35,780
manager
13,232
senior
8,380
lead
3,714
intern
836
entry
723

Skills employers mention

Top skills across 62,665 tracked postings in the available jobs snapshot.

Excel
760
Aws
454
Sql
363
Python
356
Microsoft Office
351
Word
340
Outlook
308
Powerpoint
296
Agile
294
Ci/Cd
261
ADVERTISED PAY$88.5K/ year

Median across 9,558 postings with pay data, expressed in USD.

Salary by seniority

manager$115.0K/ year1,835 postings
senior$115.0K/ year1,511 postings
lead$125.0K/ year901 postings
intern$52.0K/ year48 postings
entry$40.0K/ year210 postings

Advertised posting medians do not describe all employees or roles.

THE PEOPLE BUILDING THE FIELD

Founders and leaders

14,343 founders and chief executives across 10,682 companies.

Expand panel +
12 profiles

Swipe or scroll horizontally to browse.

Education networks

2,655 profiles with education records.

Harvard University
387
Stanford University
378
Massachusetts Institute of Technology
377
University of Pennsylvania
211
University of California (Berkeley)
204
Cornell University
157
Harvard Business School
156
Yale University
117

Prior employers

212 profiles with prior-work records.

McKinsey
49
Microsoft
31
Google
28
Amazon
22
Boston Consulting Group
18
Intel
18
Apple
13
Bain
12

Profiles cover recorded founders and leaders; contact details remain in Radar.

NEWS INTELLIGENCE

How this industry appears in the news

245,045 articles in the measured 12-month window.

Expand panel +
245,045articles in the measured year
67,695articles in 2026Q1
75.0%positive tone in the latest complete year

News volume trends

Life Sciences coverage across United States · articles per complete quarter

043,80487,608131,412175,2162021Q2: 75,1452021Q22021Q3: 65,5912021Q4: 56,0532022Q1: 61,5652022Q2: 58,4872022Q22022Q3: 55,3552022Q4: 59,3512023Q1: 60,5472023Q2: 73,8852023Q22023Q3: 60,3022023Q4: 64,6912024Q1: 71,6142024Q2: 72,8252024Q22024Q3: 66,6552024Q4: 65,0992025Q1: 152,3622025Q2: 57,7672025Q22025Q3: 63,9522025Q4: 56,4662026Q1: 67,6952026Q1
View quarterly article counts
QuarterArticles
2021Q275,145
2021Q365,591
2021Q456,053
2022Q161,565
2022Q258,487
2022Q355,355
2022Q459,351
2023Q160,547
2023Q273,885
2023Q360,302
2023Q464,691
2024Q171,614
2024Q272,825
2024Q366,655
2024Q465,099
2025Q1152,362
2025Q257,767
2025Q363,952
2025Q456,466
2026Q167,695

Article volume measures coverage, not market sales.

Tone of coverage over time

2021
174,795 positive · 3,711 neutral · 62,382 negative
2022
173,997 positive · 3,601 neutral · 56,840 negative
2023
201,314 positive · 4,269 neutral · 53,507 negative
2024
212,257 positive · 4,449 neutral · 59,071 negative
2025
247,289 positive · 5,248 neutral · 77,212 negative

Leading coverage topics

Life Sciences coverage across United States · ranked by full-period article count.

Covid 19 Vaccine Development And Efficacy Trials39,155 articles in the full recorded period
3,816 recent · 1,137 prior
Oncology And Targeted Therapy Advancements28,440 articles in the full recorded period
5,253 recent · 7,172 prior
Covid 19 Vaccination Campaigns And Rollout Strategies23,158 articles in the full recorded period
2,429 recent · 567 prior
Rare Disease Therapies And Orphan Drugs22,835 articles in the full recorded period
4,860 recent · 6,623 prior
Economy News: Inflation Rate Analysis22,793 articles in the full recorded period
5,403 recent · 4,499 prior
Gene Therapy And Crispr Technologies19,287 articles in the full recorded period
3,916 recent · 5,313 prior
Drug Pricing And Reimbursement Strategies19,105 articles in the full recorded period
6,323 recent · 4,596 prior
Vaccine Research And Production Methods14,227 articles in the full recorded period
1,534 recent · 1,914 prior
Macroeconomic Policy And Global Economics13,875 articles in the full recorded period
2,509 recent · 4,830 prior
Generic Drug Development And Market Trends13,278 articles in the full recorded period
3,980 recent · 3,287 prior

Recent and prior counts use the source comparison windows.

Topics gaining and losing attention

Life Sciences coverage across United States

KeywordRecentPriorChange
vaccine candidates3,157898252%
vaccine trials2,962904228%
vaccination campaigns2,752555396%
vaccine immunogenicity2,473668270%
mass vaccination sites2,021272643%
vaccination coverage1,516202650%
vaccine effectiveness study1,400251458%
angel investors1,344590128%
covid-19 vaccine development1,335238461%
pandemic vaccine stockpiling1,294242435%
investigational new vaccine4511,069-58%
cell-based therapies6191,059-42%
viral vector vaccines6841,048-35%
cancer biomarkers6701,040-36%
diagnostic biotechnology570948-40%

Event and signal lenses

Life Sciences coverage across United States

All complete annual cohorts shown
Rising

Regulatory Risk

290,712 classified articles

core inflation rate, inflation outlook, inflation breakdown

52.8% critical · 34.6% positive
Rising

Funding Momentum

102,225 classified articles

angel investors, vaccine candidates, vaccine trials

49.1% critical · 55.2% positive
Rising

Growth

175,378 classified articles

gdp acceleration, gdp growth rate, economic output growth

49.7% critical · 39.6% positive

Life Sciences coverage across United States. Topic labels describe recorded classifications and can include broad context.

RESEARCH SIGNALS

What Life Sciences research is working on

6,260 papers in the recorded india scope.

Expand panel +
6,260papers
53,147worldwide comparison pool
6,260India-affiliated papers

Research orientation

Breakthrough
2,038
Promising
1,943
Descriptive
1,098
Problem-identifying
567
Cautionary
360
Comparative
175
Critical
79

Contribution mix

Empirical
3,753
Methods-led
1,242
Reviews
1,058
Position pieces
198
Theoretical
9

Tone counts: 5,526 positive · 456 neutral · 278 negative.

Common problems researchers identify
646 papers · 10.3% of this field
  • Agriculture59 papers
  • Antibiotic resistance53 papers
  • Biotechnology46 papers
  • Antimicrobial34 papers
  • Public health31 papers
  • Production28 papers
  • Population27 papers
  • Antibiotics24 papers

Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob

Cautions
360 papers · 5.8% of this field
  • Gene21 papers
  • Agriculture19 papers
  • Antibody15 papers
  • Mutation15 papers
  • In vivo14 papers
  • Population12 papers
  • Antibiotic resistance11 papers
  • Mitochondrion11 papers

Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases

Opportunities
3,981 papers · 63.6% of this field
  • Gene284 papers
  • In vivo224 papers
  • Antibody125 papers
  • Gene expression121 papers
  • Cell culture115 papers
  • Messenger RNA110 papers
  • Transcription103 papers
  • Cell101 papers

Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro

Leading institutions

Harvard University
86,693
Howard Hughes Medical Institute
74,901
Cornell University
42,772
Stanford University
38,500
National Institutes of Health
35,881
Massachusetts Institute of Technology
33,017

Leading researchers

Daniel Merenstein
9,186
Colin Hill
8,812
Francisco Guarner
8,812
Gregor Reid
8,812
Glenn R. Gibson
8,812
Ahmad Almilaji
8,696
Kalina Szteyn
8,696
Evelyn Fein
8,696

Highly cited breakthrough-labelled papers

  • U1 snRNP regulates cancer cell migration and invasion in vitro7,224 citations
  • Comprehensive molecular profiling of lung adenocarcinoma5,754 citations
  • The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets4,863 citations
  • Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway4,674 citations
  • Circular RNAs are abundant, conserved, and associated with ALU repeats4,505 citations

Common problems researchers identify

632 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

Challenges in Biomanufacturing TechnologiesCommon problems researchers identify · 01

Challenges in Biomanufacturing Technologies

116 papers

18.4% of this theme group

Researchers highlight technical hurdles in synthetic biology, enzymatic processes, and nanotech for scalable bioproducts.

Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)

Microbial Enzymes: Tools for Biotechnological Processes

Medical biofilms

View research history
YearShare index
202268.2
202370.7
202484.8
202568.0
Foodborne Disease and Contamination RisksCommon problems researchers identify · 02

Foodborne Disease and Contamination Risks

99 papers

15.7% of this theme group

Studies flag rising public‑health threats from mycotoxins, pathogens, and unsafe fresh produce.

Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)

The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities

A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments

View research history
YearShare index
2022299.5
2023264.5
2024275.8
2025304.9
Genomic Instability in CancerCommon problems researchers identify · 03

Genomic Instability in Cancer

98 papers

15.5% of this theme group

Papers discuss mutation patterns, DNA methylation complexities, and metabolic alterations driving tumor progression.

Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)

Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research

Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine

View research history
YearShare index
2022970.7
20231201.3
2024865.0
2025805.7
Abiotic Stress in Modern AgricultureCommon problems researchers identify · 04

Abiotic Stress in Modern Agriculture

96 papers

15.2% of this theme group

Works examine genetic engineering and hormone manipulation to improve crop resilience to environmental stresses.

Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)

Genetic Engineering for Modern Agriculture: Challenges and Perspectives

Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants

View research history
YearShare index
20221468.0
20231499.2
20241649.2
20251814.4
Micronutrient Deficiencies and Food ScienceCommon problems researchers identify · 05

Micronutrient Deficiencies and Food Science

93 papers

14.7% of this theme group

Research points to gaps in nutrient biofortification and microbial fermentation for healthier food products.

Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)

Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016

Food fermentations: Microorganisms with technological beneficial use

View research history
YearShare index
2022120.4
2023116.8
2024112.7
2025121.4
Escalating Antibiotic ResistanceCommon problems researchers identify · 06

Escalating Antibiotic Resistance

70 papers

11.1% of this theme group

Authors outline mechanisms and global impact of antimicrobial resistance across clinical and environmental settings.

Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)

An overview of the antimicrobial resistance mechanisms of bacteria

The global threat of antimicrobial resistance: science for intervention

View research history
YearShare index
2022882.6
2023836.2
2024909.1
2025967.1
Insecticide Resistance and Pest ManagementCommon problems researchers identify · 07

Insecticide Resistance and Pest Management

60 papers

9.5% of this theme group

Studies reveal growing resistance in vectors and crops, urging new integrated control strategies.

Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)

Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions

Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens

View research history
YearShare index
20223.3
20233.1
20244.4
20254.4

Cautions

353 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

DNA Repair and Mutation ConcernsCautions · 01

DNA Repair and Mutation Concerns

87 papers

24.6% of this theme group

Investigations caution about unintended genomic instability when targeting repair pathways.

DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)

Examining the link between chromosomal instability and aneuploidy in human cells

Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations

View research history
YearShare index
2022100.9
2023139.8
202492.1
202580.4
Immune Modulation Risks in TherapiesCautions · 02

Immune Modulation Risks in Therapies

64 papers

18.1% of this theme group

Works warn of altered B‑cell and T‑cell responses that may increase infection susceptibility.

Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs

T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data

View research history
YearShare index
2022541.4
2023602.3
2024449.0
2025446.3
Food Safety and Nanomaterial ExposureCautions · 03

Food Safety and Nanomaterial Exposure

51 papers

14.4% of this theme group

Research advises careful assessment of nanomaterials’ impact on nutrition and consumer health.

Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)

Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters

Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption

View research history
YearShare index
2022122.1
2023119.4
2024117.7
2025151.8
Livestock Nutrition and Environmental Trade‑offsCautions · 04

Livestock Nutrition and Environmental Trade‑offs

41 papers

11.6% of this theme group

Analyses highlight potential drawbacks of feed additives on animal performance and methane emissions.

Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)

Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis

The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst

View research history
YearShare index
2022126.6
2023122.0
2024118.1
2025128.7
Genomic Selection Implementation LimitsCautions · 05

Genomic Selection Implementation Limits

38 papers

10.8% of this theme group

Papers discuss practical challenges and bias risks in applying genomic selection to crops.

Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)

Genomic Selection for Crop Improvement

Genomic selection in plant breeding: from theory to practice

View research history
YearShare index
20222365.8
20232358.9
20242089.0
20251591.6
Integrated Pest Management ComplexityCautions · 06

Integrated Pest Management Complexity

37 papers

10.5% of this theme group

Studies caution that biological controls may face ecological constraints and resistance development.

PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)

The use of fungal entomopathogens as endophytes in biological control: a review

Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?

View research history
YearShare index
20221438.5
20231479.5
20241635.4
20251802.2
Antibiotic Use and Resistance SpilloverCautions · 07

Antibiotic Use and Resistance Spillover

35 papers

9.9% of this theme group

Research highlights how veterinary antibiotic practices can propagate resistance to human pathogens.

Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)

Multidrug evolutionary strategies to reverse antibiotic resistance

Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review

View research history
YearShare index
2022882.6
2023836.2
2024909.1
2025967.1

Opportunities

3,882 papers · 7 recurring themes
7 cards

Swipe or scroll horizontally to browse.

Probiotic and Postbiotic InnovationsOpportunities · 01

Probiotic and Postbiotic Innovations

759 papers

19.6% of this theme group

Emerging work explores microbial products for improving human health and animal performance.

Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)

Probiotics, their health benefits and applications for developing healthier foods: a review

Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance

View research history
YearShare index
20222423.9
20232253.6
20242334.8
20251976.5
Gene Regulation and Cancer TherapyOpportunities · 02

Gene Regulation and Cancer Therapy

750 papers

19.3% of this theme group

Studies investigate apoptosis modulation and gene knockdown strategies for targeted oncology treatments.

Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)

PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development

Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis

View research history
YearShare index
2022362.1
2023395.1
2024257.0
2025266.6
Cell‑Based ImmunotherapiesOpportunities · 03

Cell‑Based Immunotherapies

513 papers

13.2% of this theme group

Research advances antibody targets and T‑cell engineering to enhance anti‑tumor immunity.

Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes

View research history
YearShare index
2022288.2
2023337.0
2024225.1
2025206.3
Epigenetic Editing for DiseaseOpportunities · 04

Epigenetic Editing for Disease

497 papers

12.8% of this theme group

Papers present tools to reshape DNA methylation and chromatin for therapeutic benefit.

DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)

Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders

MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition

View research history
YearShare index
2022223.4
2023282.6
2024197.1
2025160.5
Nanotech Molecular ImagingOpportunities · 05

Nanotech Molecular Imaging

472 papers

12.2% of this theme group

Innovations combine fluorescence and MRI probes for real‑time tracking of biological processes.

In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)

Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases

Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl

View research history
YearShare index
2022478.9
2023520.7
2024397.9
2025411.9
Genomic Resources for Crop BreedingOpportunities · 06

Genomic Resources for Crop Breeding

453 papers

11.7% of this theme group

Works showcase sequencing and germplasm diversity to accelerate trait improvement.

Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)

Genotyping‐by‐Sequencing for Plant Breeding and Genetics

Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding

View research history
YearShare index
202256.3
202351.6
202446.4
202553.9
RNA‑Based Regulation StrategiesOpportunities · 07

RNA‑Based Regulation Strategies

438 papers

11.3% of this theme group

Studies focus on mRNA modifications and microRNA pathways to control gene expression.

Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)

m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation

Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc

View research history
YearShare index
2022228.7
2023195.9
2024157.1
2025138.8

How this field compares with the research baseline

Orientation shares compared with 25,000 papers in the reference sample.

Research orientationThis fieldReference sample
Breakthrough32.6%26.3%
Promising31.0%37.4%
Descriptive17.5%17.5%
Problem-identifying9.1%9.6%
Cautionary5.8%4.7%
Comparative2.8%3.7%
Critical1.3%0.8%

Concerns receiving less research attention

Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.

Concern / example paperPapersShareRaised as a problemWorldwide share
Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities180.3%2 (11.1%)0.21%
Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste40.07%1 (25.0%)0.15%
Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis30.05%1 (33.3%)0.03%
Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya10.02%1 (100.0%)0.01%
Energy & datacenter footprint00.0%0 (%)0.0%
Water use00.0%0 (%)0.0%
Carbon & emissions of compute00.0%0 (%)0.0%
Labour & data work00.0%0 (%)0.0%
Concentration of compute power00.0%0 (%)0.0%

Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.

Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.

INNOVATION SIGNALS

Who files Life Sciences patents in the United States

Published patent filings in the recorded source window.

Expand panel +
457,918filings 2016–2025
8,000assignees
51,616peak annual filings

Filing momentum

014,84029,67944,51959,3582016: 36,88420162017: 41,3252018: 41,77820182019: 45,2432020: 48,41120202021: 51,6162022: 49,78820222023: 49,6882024: 48,73920242025: 44,4462025

Who files the most

Genentech
18,078
UNIV California
17,948
Regeneron Pharma
16,082
Amgen
10,495
Monsanto
9,742
UNIV Pennsylvania
8,521
Harvard College
7,460
UNIV Texas
7,378
DEMAND, SUPPLY & PLACE

Where demand signals run ahead of mapped supply — the United States

Compare demand signals in the United States’s newsflow with the life sciences categories mapped to each signal.

Expand panel +
HOW TO READ THE GAP

Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.

The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.

COMPARISON PERIOD2025-07-01 to 2026-07-01Against 2024-07-01 to 2025-07-01Explore the signals ↓

The opportunity, in one view

Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.

Swipe horizontally to compare all columns →

8 the United States demand signals compared with mapped life sciences supply
Signal familySignal percentileSupply percentileRelative gapGap (points)Signal share vs prior year
Maternal & child health ↗Disease Burden92.90.0+92.9+110.1%
Layoffs & income shocks ↗Spending Pressure85.760.0+25.7+57.7%
Infectious outbreaks ↗Disease Burden35.730.0+5.7+45.9%
Air pollution ↗Environmental Driver21.430.0-8.6-18.3%
Cancer burden ↗Disease Burden35.780.0-44.3+2.5%
Diabetes, hypertension & cardiac burden ↗Disease Burden21.4100.0-78.6+21.4%
Mental health ↗Disease Burden78.6—No matching category—+63.1%
Ageing & elder care ↗Disease Burden28.6—No matching category—-43.4%

Showing all 8 signals. Select a family for its history and mapped categories.

Where the signals are loudest

All 12 city readings for these demand families in the comparison geography. the United States is highlighted.

Mentions per 10,000 articles

Each city’s reading is a share of its own coverage.

Kentucky172.3

Maternal & child health · Mental health · Layoffs & income shocks

Delaware159.7

Maternal & child health · Ageing & elder care · Cancer burden

Indiana137.6

Maternal & child health · Mental health · Layoffs & income shocks

Maryland130.4

Maternal & child health · Mental health · Layoffs & income shocks

Connecticut124.9

Mental health · Maternal & child health · Ageing & elder care

South Carolina124.2

Maternal & child health · Layoffs & income shocks · Infectious outbreaks

Iowa121.1

Maternal & child health · Layoffs & income shocks · Mental health

Colorado120.9

Mental health · Maternal & child health · Air pollution

Wisconsin120.9

Maternal & child health · Mental health · Ageing & elder care

Louisiana120.9

Maternal & child health · Mental health · Layoffs & income shocks

Tennessee116.2

Layoffs & income shocks · Maternal & child health · Mental health

North Carolina114.7

Mental health · Maternal & child health · Layoffs & income shocks

Inside the leading signals

Open any signal for its quarterly history
DISEASE BURDENMaternal & child health+92.9percentile-point gap
THE OPERATING HYPOTHESIS

Maternal and child burden can pull immunisation, nutrition and pediatric care demand.

18.23mentions per 10,000 articles+110.1%share change vs prior year

Mapped life sciences categories

  • Nutritional Formula992

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

081725342024Q3: 72024Q32024Q4: 72024Q42025Q1: 72025Q12025Q2: 112025Q22025Q3: 292025Q32025Q4: 92025Q42026Q1: 72026Q12026Q2: 112026Q2
View quarterly signal counts
Maternal & child health in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q313337.82
2024Q414147.97
2025Q119627.84
2025Q2186411.69
2025Q3800929.39
2025Q411689.68
2026Q111097.68
2026Q291911.94

Where this signal concentrates in the comparison geography

Delaware62.8 / 10,000
Kentucky61.4 / 10,000
South Carolina60.0 / 10,000
SPENDING PRESSURELayoffs & income shocks+25.7percentile-point gap
THE OPERATING HYPOTHESIS

Layoff cycles can pull discretionary spend back toward value offerings.

24.69mentions per 10,000 articles+57.7%share change vs prior year

Mapped life sciences categories

  • Biopharmaceuticals4,752

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

091827362024Q3: 152024Q32024Q4: 142024Q42025Q1: 132025Q12025Q2: 192025Q22025Q3: 242025Q32025Q4: 312025Q42026Q1: 192026Q12026Q2: 242026Q2
View quarterly signal counts
Layoffs & income shocks in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q3269215.79
2024Q4265714.98
2025Q1345713.81
2025Q2305519.17
2025Q3668724.54
2025Q4376131.16
2026Q1284319.69
2026Q2188524.49

Where this signal concentrates in the comparison geography

Tennessee44.9 / 10,000
Arkansas41.1 / 10,000
Iowa26.8 / 10,000
DISEASE BURDENInfectious outbreaks+5.7percentile-point gap
THE OPERATING HYPOTHESIS

Outbreak pressure can pull testing, surveillance and rapid-care demand at short notice.

6.38mentions per 10,000 articles+45.9%share change vs prior year

Mapped life sciences categories

  • In Vitro Diagnostics1,146

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0368112024Q3: 32024Q32024Q4: 42024Q42025Q1: 32025Q12025Q2: 52025Q22025Q3: 92025Q32025Q4: 32025Q42026Q1: 32026Q12026Q2: 42026Q2
View quarterly signal counts
Infectious outbreaks in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q36733.95
2024Q48004.51
2025Q19813.92
2025Q28605.4
2025Q326509.72
2025Q44653.85
2026Q14403.05
2026Q23684.78

Where this signal concentrates in the comparison geography

Kentucky19.4 / 10,000
South Carolina14.6 / 10,000
Louisiana14.3 / 10,000
ENVIRONMENTAL DRIVERAir pollution-8.6percentile-point gap
THE OPERATING HYPOTHESIS

Sustained air-quality stress can pull respiratory and cardiac care demand with it.

6.47mentions per 10,000 articles-18.3%share change vs prior year

Mapped life sciences categories

  • In Vitro Diagnostics1,146

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0369112024Q3: 62024Q32024Q4: 82024Q42025Q1: 72025Q12025Q2: 92025Q22025Q3: 52025Q32025Q4: 52025Q42026Q1: 72026Q12026Q2: 82026Q2
View quarterly signal counts
Air pollution in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q310756.31
2024Q414458.15
2025Q119067.62
2025Q215729.86
2025Q316265.97
2025Q46465.35
2026Q110767.45
2026Q26278.14

Where this signal concentrates in the comparison geography

Louisiana16.4 / 10,000
Delaware14.5 / 10,000
Colorado14.5 / 10,000
DISEASE BURDENCancer burden-44.3percentile-point gap
THE OPERATING HYPOTHESIS

Cancer burden can pull screening, diagnostics and oncology capacity demand.

7.52mentions per 10,000 articles+2.5%share change vs prior year

Mapped life sciences categories

  • Biopharmaceuticals4,752
  • In Vitro Diagnostics1,146

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

0369122024Q3: 62024Q32024Q4: 82024Q42025Q1: 62025Q12025Q2: 82025Q22025Q3: 62025Q32025Q4: 102025Q42026Q1: 72026Q12026Q2: 82026Q2
View quarterly signal counts
Cancer burden in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q310876.38
2024Q415518.75
2025Q116166.46
2025Q213068.19
2025Q316466.04
2025Q4123810.26
2026Q111147.72
2026Q26248.11

Where this signal concentrates in the comparison geography

Delaware15.3 / 10,000
Missouri14.4 / 10,000
Maryland12.9 / 10,000
DISEASE BURDENDiabetes, hypertension & cardiac burden-78.6percentile-point gap
THE OPERATING HYPOTHESIS

Chronic cardiometabolic burden can turn into decades of management demand per patient.

4.5mentions per 10,000 articles+21.4%share change vs prior year

Mapped life sciences categories

  • Medical Devices5,358
  • Biopharmaceuticals4,752

Companies can appear in multiple categories; these counts are not a unique-company total.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

024682024Q3: 32024Q32024Q4: 32024Q42025Q1: 42025Q12025Q2: 42025Q22025Q3: 32025Q32025Q4: 62025Q42026Q1: 42026Q12026Q2: 52026Q2
View quarterly signal counts
Diabetes, hypertension & cardiac burden in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q35553.26
2024Q45393.04
2025Q110174.06
2025Q26934.35
2025Q39083.33
2025Q48056.67
2026Q16374.41
2026Q24135.36

Where this signal concentrates in the comparison geography

Connecticut11.1 / 10,000
Missouri8.4 / 10,000
Mississippi7.2 / 10,000
DISEASE BURDENMental health—supply not mapped
THE OPERATING HYPOTHESIS

Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.

14.86mentions per 10,000 articles+63.1%share change vs prior year

Mapped life sciences categories

This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

05914192024Q3: 92024Q32024Q4: 102024Q42025Q1: 72025Q12025Q2: 92025Q22025Q3: 162025Q32025Q4: 122025Q42026Q1: 152026Q12026Q2: 122026Q2
View quarterly signal counts
Mental health in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q316879.9
2024Q4183210.33
2025Q119197.67
2025Q214649.19
2025Q3438416.09
2025Q4152112.6
2026Q1229315.88
2026Q293512.15

Where this signal concentrates in the comparison geography

Colorado42.7 / 10,000
Mississippi32.6 / 10,000
Connecticut29.9 / 10,000
DISEASE BURDENAgeing & elder care—supply not mapped
THE OPERATING HYPOTHESIS

An ageing base can shift demand toward geriatric, home and chronic care.

7.85mentions per 10,000 articles-43.4%share change vs prior year

Mapped life sciences categories

This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.

Quarterly share of the United States coverage

Mentions per 10,000 articles · zero baseline

051015202024Q3: 122024Q32024Q4: 172024Q42025Q1: 122025Q12025Q2: 132025Q22025Q3: 62025Q32025Q4: 82025Q42026Q1: 82026Q12026Q2: 82026Q2
View quarterly signal counts
Ageing & elder care in the United States coverage
QuarterMentionsPer 10,000 articles
2024Q3209212.27
2024Q4302717.07
2025Q1316612.65
2025Q2222213.94
2025Q318016.61
2025Q410428.63
2026Q112948.96
2026Q26898.95

Where this signal concentrates in the comparison geography

Delaware24.3 / 10,000
Connecticut23.5 / 10,000
Indiana16.4 / 10,000
RESEARCH & CHANGING CONVERSATIONS

Related research and changing coverage

the United States life sciences coverage

Expand panel +
RESEARCH CONTEXT · 2017

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Hypertension

7,315 citations in the snapshot

RESEARCH CONTEXT · 2019

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

6,114 citations in the snapshot

RESEARCH CONTEXT · 2019

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

4,494 citations in the snapshot

RESEARCH CONTEXT · 2019

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

4,422 citations in the snapshot

What is growing in this coverage

the United States coverage of this page's demand families

KeywordRecent articlesPrior articlesShare change
post-covid complications1,1031051194.7%
last-mile vaccine delivery14523677.0%
epidemic death tolls31353627.8%
snow rescue19936581.3%
disease outbreak deaths700152467.6%
contagion mortality rates22049453.3%

Share changes describe coverage in the stated comparison periods, not search demand or market size.

GEOGRAPHIC FOOTPRINT

Where companies are based

Company counts, hiring and disclosed funding across the recorded hubs.

Expand panel +
8 cards

Swipe or scroll horizontally to browse.

UNDERSTAND THE LANDSCAPE

Life Sciences in the United States: key questions

Clear definitions for making better comparisons.

What does this landscape measure?

It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.

Can segment counts be added together?

No. A company can belong to several segments, so segment counts and funding can overlap.

What does a missing figure mean?

A dash or unavailable panel means the current reviewed source snapshot does not support that figure.

Company ecosystem snapshot: 5 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.

Canonical landscape ↗
Coming soon